Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
raludotatug deruxtecan + carboplatin
- Development stage
- Phase 2
- Lead developer
- Daiichi Sankyo
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Raludotatug deruxtecan + carboplatin is a combination therapy being investigated for the treatment of relapsed high-grade serous ovarian cancer[1][3][7]. Raludotatug deruxtecan is an antibody-drug conjugate (ADC) consisting of a humanized IgG1 monoclonal antibody targeting cadherin-6 (CDH6), conjugated to deruxtecan, a cytotoxic DNA topoisomerase I inhibitor[4][6][7]. Carboplatin is a platinum-based chemotherapeutic agent with DNA cross-linking activity. This combination is administered intravenously, with carboplatin provided as standard chemotherapy in cycles and raludotatug deruxtecan administered until disease progression or discontinuation[1][3]. The ADC targets CDH6 on tumor cells, is internalized, and releases its DXd payload intracellularly to inhibit topoisomerase I, causing DNA damage and apoptosis. The combination is intended to increase tumor cell killing via dual mechanisms—targeted cytotoxicity (ADC) and DNA damage (platinum chemotherapy).
- Other names
- R-DXd + carboplatinraludotatug deruxtecan + carboplatin
02
Targets
CDH6 (Cadherin-6)DNA
Beyond the preview
Go deeper on raludotatug deruxtecan + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on raludotatug deruxtecan + carboplatin.